United Therapeutics (UTHR) Stock Rating Upgraded by BidaskClub

United Therapeutics (NASDAQ:UTHR) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

A number of other research analysts have also weighed in on the stock. Wedbush raised their target price on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an “outperform” rating in a research note on Thursday, August 2nd. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Thursday, August 16th. HC Wainwright set a $95.00 price target on shares of United Therapeutics and gave the company a “hold” rating in a research report on Monday, August 13th. Cowen reaffirmed a “hold” rating and set a $110.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Finally, Credit Suisse Group lifted their price target on shares of United Therapeutics from $104.00 to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $138.86.

UTHR opened at $125.94 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. United Therapeutics has a 1-year low of $100.57 and a 1-year high of $152.55. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 27.85 and a beta of 1.24.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million for the quarter, compared to analyst estimates of $368.63 million. During the same period last year, the company posted $4.37 EPS. The business’s revenue was up .0% on a year-over-year basis. sell-side analysts forecast that United Therapeutics will post 14.77 EPS for the current fiscal year.

In other news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the sale, the director now owns 3,925 shares of the company’s stock, valued at approximately $463,150. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,100 shares of company stock worth $977,508. Corporate insiders own 8.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. WINTON GROUP Ltd acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $3,784,000. Andra AP fonden acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $8,679,000. California Public Employees Retirement System increased its holdings in United Therapeutics by 8.8% in the 2nd quarter. California Public Employees Retirement System now owns 194,104 shares of the biotechnology company’s stock valued at $21,963,000 after purchasing an additional 15,752 shares during the last quarter. Worldquant Millennium Quantitative Strategies LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $347,000. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its holdings in United Therapeutics by 18.9% in the 2nd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 33,400 shares of the biotechnology company’s stock valued at $3,779,000 after purchasing an additional 5,300 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Story: Earnings Per Share (EPS) Explained

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply